Immunic, Inc. Common Stock(IMUX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
IMUX iron condor setups
IMUX expected move
IMUX IV rank history
IMUX Fibonacci levels
IMUX insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
IMUX
$9.35
—
Snapshot
$9.35
After hours
$9.35
+0.00%
- 52-Week Range
- $5.06 – $17.43
- YTD
- +60.29%
- IV Rank (30D)
- 76.31
- Straddle Price
- $1.80
- P/C Vol Ratio
- 0.41
- Market Cap
- $0.1B
Fair Value
+27.3% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.05 |
| Cost of Equity (CAPM) | 10.72% (VRP-adj) |
| WACC | 10.75% |
| Volatility Risk Premium | +338.8pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -87.5% |
| Book / Price | 49.1% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $13.90 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $12.17 |
| Bollinger Width / SMA20 | 561.7% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $0B |
Peers used for multiples: ABT, PFE, REGN
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$11.89
Deviation
+27.3%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 33.0× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.0× · 3 peers |
| Peer P/B | $11.89 | 100% | median 2.6× · 3 peers |
| Peer P/S | n/a | 0% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $13.90 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $8.90 | 0% | 7 strikes · skew +0.30 |
As of 2026-09-25 · updated
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.1B
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier fu…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +9.16% | 7 |
| Feb | +10.56% | 7 |
| Mar | -7.62% | 7 |
| Apr | -6.53% | 8 |
| May | +0.87% | 8 |
| Jun | +1.80% | 8 |
| Jul | +9.19% | 8 |
| Aug | +2.20% | 8 |
| Sep | -12.63% | 8 |
| Oct | -19.39% | 7 |
| Nov | -3.94% | 7 |
| Dec | +1.47% | 7 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $11.83
SMA 50: $13.79
SMA 200: $11.30
Current: $9.50
EMA 12: $10.67
EMA 26: $12.05
MACD: -1.3741 | Signal: -0.1845
BEARISH
ADX (14): 43.64
STRONG TREND
+DI: 10.65
−DI: 36.84
Momentum Oscillators
RSI (14): 26.04
OVERSOLD
Stoch %K: 5.58
Stoch %D: 7.52
Williams %R: -89.59
Volume & Volatility
BB Upper: $15.69
BB Lower: $7.98
NEUTRAL
OBV: -1,246,036
Vol SMA 20: 380,806
Vol ROC: -20.77%
ATR: $0.86
True Range: $0.38
HV 20: 76.8%
HV 30: 68.8%
HV 60: 63.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-09-26T00:00:00 – 2026-09-24T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: IMUX CURRENT PRICE: $14.10
Executive Summary BULLISH (Confidence Level: 6/10)
Key drivers:
- Positive news sentiment from recent headlines
- Medium-term trend direction aligning with short-term uptrend
Primary risks:
- High volatility (beta >1.5)
- Potential for a retracement if technical indicators diverge from news sentiment
Investment thesis: IMUX's recent price action is driven by positive news headlines, particularly the Celiac Disease Market Report 2025-2035 and Immunic's Ulcerative Colitis study showing positive data. While high volatility remains a concern, the medium-term trend direction suggests an uptrend may persist.
Recent news sentiment impact: The overall news sentiment is NEUTRAL, with some positive headlines (Celiac Disease report) and neutral ones (other articles). However, the Immunic's Ulcerative Colitis study showing positive data contributes to a bullish bias.
Technical Analysis TREND DIRECTION: Short-term (1-4 weeks): UPTREND, Medium-term (1-3 months): UPTREND
SUPPORT/RESISTANCE LEVELS:
- Key price levels from moving averages and technical patterns:
- SMA 20: $14.33
- EMA 12: $14.15
- Resistance: Upper Bollinger Band ($15.61)
- Support: Lower Bollinger Band ($13.06)
MOMENTUM SIGNALS:
- RSI interpretation: Neutral (48.58 <70, >30)
- MACD signal: Bearish (negative histogram)
- Bollinger Bands position: Squeeze
VOLUME ANALYSIS:
- Volume trends and institutional interest signals:
- On-Balance Volume (OBV): 1274632.70
- Volume Rate of Change: -27.25%
News & Sentiment Analysis Recent Headlines Summary: The news headlines are primarily neutral, with some positive sentiment from the Celiac Disease report.
Sentiment Assessment: NEUTRAL
Catalyst Identification: Immunic's Ulcerative Colitis study showing positive data (2023-04-06)
Market Narrative: The recent price action is driven by the positive news headlines, which aligns with the medium-term uptrend direction.
Risk & Volatility Assessment Beta Interpretation: High risk relative to market (beta >1.5)
Volatility Regime: Current volatility levels are higher than historical averages.
Options Market Signals: IV rank: 7.8% (Low) Current IV: 144.5% Expected Move: $3.35 (39 DTE), 7-DTE: $3.00
Downside Protection: Support levels and risk management considerations:
- Lower Bollinger Band ($13.06)
Market Context & Positioning Sector Performance: Relative strength vs sector/market: Strong
Institutional Activity: Volume patterns suggesting institutional interest: + On-Balance Volume (OBV): 1274632.70 + Institutional participation in options market: 196 calls vs 49 puts
Correlation Analysis: How stock moves relative to market (R-squared interpretation): + Correlation coefficient: 0.25 (low correlation)
Relative Valuation: Position within trading range: + Relative to its peers and the broader market, IMUX is undervalued
Key Levels & Action Items Critical Price Levels:
- Resistance: Upper Bollinger Band ($15.61)
- Support: Lower Bollinger Band ($13.06)
Breakout/Breakdown Levels:
- Breakout above $15.61 for further upside
- Breakdown below $13.06 for potential reversal
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches (no earnings data available)
Risk Management: Stop-loss levels and position sizing considerations: + Consider placing a stop-loss order around the Lower Bollinger Band ($13.06) to manage risk
Note: The analysis is based on the provided data, and opinions may vary depending on individual perspectives and market conditions.
Generated
News
Earnings History
5 of 5 under expected move
Avg Expected Move
64.32%
Avg Actual Move
3.52%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-11-07 | After-Close | 123.97% | 2.48% | 0.02x | Within |
| 2025-08-07 | After-Close | 38.79% | 3.35% | 0.09x | Within |
| 2025-11-13 | Pre-Market | 75.67% | 6.24% | 0.08x | Within |
| 2026-02-26 | Pre-Market | 63.14% | 2.40% | 0.04x | Within |
| 2026-08-13 | After-Close | 20.05% | 3.14% | 0.16x | Within |
Options Activity
- IV Rank (30D)
- 76.31
- IV Rank (7D)
- 76.31
- Avg IV
- 406.9%
- Straddle (30D)
- $1.80
- Straddle (7D)
- $1.80
- P/C Volume
- 0.41
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.57
- Correlation (SPY)
- 25.4%
- R²
- 0.06
- Ann. Volatility
- 80.6%
- SPY Volatility
- 13.0%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
? 13F Guide
Diluted shares outstanding: 27,893,353 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$4.64M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SIMPLEX TRADING, LLC Custodian | $2.15M | 46.36% | 2026-06-30 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $1.82M | 39.24% | 2026-06-30 |
| 3 | JANE STREET GROUP, LLC Custodian | $235.16K | 5.07% | 2026-06-30 |
| 4 | CITADEL ADVISORS LLC Custodian | $211.49K | 4.56% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $189.05K | 4.08% | 2026-06-30 |
| 6 | Belvedere Trading LLC | $32.19K | 0.69% | 2026-06-30 |
2 filers$865.33K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $774.65K | 89.52% | 2026-06-30 |
| 2 | SIMPLEX TRADING, LLC Custodian | $90.68K | 10.48% | 2026-06-30 |
Insider Activity
Latest: 2026-09-18
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Robert Thorvald Nagel | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-09-18 | BVF INC/IL | Director | Award (A) | — | — | EDGAR | |
| 2026-08-10 | Elena Ridloff | Director | Grant (A) | +50,740 opt | — | EDGAR | |
| 2026-07-07 | Simona Skerjanec | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-07-07 | Richard Alan Rudick | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-07-07 | Joerg Neermann | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-07-07 | BARCLAY A PHILLIPS | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-07-07 | Jon Congleton | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-06-29 | TAMAR D HOWSON | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-06-29 | Joerg Neermann | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-06-29 | Daniel Vitt | Director | Grant (A) | +445,000 opt | — | EDGAR | |
| 2026-06-29 | Richard Alan Rudick | Director | Grant (A) | +25,370 opt | — | EDGAR | |
| 2026-06-29 | MICHAEL W BONNEY | Director | Grant (A) | +100,000 opt | — | EDGAR | |
| 2026-06-29 | Jason Tardio | President and COO | Grant (A) | +253,000 opt | — | EDGAR | |
| 2026-06-29 | Glenn Whaley | Chief Financial Officer | Grant (A) | +120,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
9 insiders · @ $9.50
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | BVF INC/IL | Director | 42,762 | $406.2K | $0 | 1 | 2026-09-18 |
| 2 | Daniel Vitt | CEO and Director | 39,188 | $372.3K | -$15.2K | 18 | 2026-06-29 |
| 3 | Andreas Muehler | Chief Medical Officer | 29,799 | $283.1K | $173.3K | 11 | 2025-07-18 |
| 4 | Manfred Groeppel | Chief Operating Officer | 27,948 | $265.5K | -$82.4K | 4 | 2021-03-02 |
| 5 | Richard Alan Rudick | Director | 23,038 | $218.9K | $200.4K | 8 | 2026-07-07 |
| 6 | Joerg Neermann | Director | 20,000 | $190.0K | $204.4K | 13 | 2026-07-07 |
| 7 | Glenn Whaley | Chief Financial Officer | 9,551 | $90.7K | $124.4K | 23 | 2026-06-29 |
| 8 | Duane Nash | Executive Chairman | 3,603 | $34.2K | $97.2K | 20 | 2025-07-18 |
| 9 | Jason Tardio | President and COO | 1,251 | $11.9K | $19.8K | 6 | 2026-06-29 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 1.0 |
| EV/EBITDA | 0.2 |
| TTM Net Income | $-0.1B |
| TTM EPS | $-3.88 |
| ROE | -87.5% |